The combined treatment was associated with downregulation of DNMT1, a reduced Bcl‑2/Bax ratio, and upregulation of HOXA9, p21, and E‑cadherin. These preclinical findings suggest that the combination of BS and DAC represents a mechanistically rationalized and promising therapeutic strategy for lung cancer that warrants further evaluation in in vivo models and early‑phase clinical trials.

1 day ago

Journal

BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • HOXA9 (Homeobox A9) • BAX (BCL2-associated X protein) • DNMT1 (DNA methyltransferase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • ANXA5 (Annexin A5)

decitabine

Composite nanovesicles for enhanced chemodynamic cancer therapy via decitabine-mediated epigenetic reactivation. (PubMed, J Control Release)

Furthermore, Dac epigenetically restores the expression of STING and GSDME via DNA demethylation, markedly augmenting cGAS-STING activation and pyroptosis. As a result, PLMD treatment enhances dendritic cell maturation and T-cell priming, ultimately achieving pronounced tumor growth inhibition and robust antitumor immune responses in a 4T1 tumor model.

1 day ago

Journal

CASP3 (Caspase 3) • NQO1 (NAD(P)H dehydrogenase, quinone 1) • GSDME (Gasdermin E)

decitabine

Enhanced Remission and Survival Outcomes with Decitabine Plus Venetoclax in Additional Sex Comb Like 1 Mutated Acute Myeloid Leukemia. (PubMed, J Vis Exp)

The use of DEC for 5 or 10 days as the hypomethylating agents combination with VEN did not affect the CR/Cri rate. In conclusion, DEC plus VEN was associated with improved clinical responses and survival signals in ASXL1-mutated AML, warranting prospective confirmation.

2 days ago

Review • Journal

ASXL1 (ASXL Transcriptional Regulator 1)

ASXL1 mutation

Venclexta (venetoclax) • decitabine

Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov)

P1, N=15, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

3 days ago

Trial completion date

sorafenib • bortezomib • decitabine

Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients (clinicaltrials.gov)

P2, N=77, Recruiting, The First Affiliated Hospital of Soochow University | Trial primary completion date: Dec 2025 --> Dec 2026

7 days ago

Trial primary completion date

NPM1 (Nucleophosmin 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha)

NPM1 mutation

azacitidine • decitabine

LS1781: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov)

P2, N=80, Recruiting, Mayo Clinic | Trial completion date: Mar 2027 --> Nov 2033 | Trial primary completion date: Mar 2027 --> Feb 2031

8 days ago

Trial completion date • Trial primary completion date

IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD4 (CD4 Molecule) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)

IDH2 mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation

cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • Truxima (rituximab-abbs) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • dexamethasone injection

10d

DNA Methylation Stochasticity is Linked to Transcriptional Variability and Convergent Epigenetic Disruption Across Genetic Subtypes of Acute Myeloid Leukemia. (PubMed, Cancer Res)

Finally, the hypomethylating drug decitabine led to reduction of DNA methylation entropy specifically in IDH2-mutant AML cells. Overall, this approach identified a convergent program of epigenetic dysregulation in leukemia, clarifying the contribution of specific genetic mutations to stochastic disruption of the epigenetic and transcriptional landscapes of AML.

10 days ago

Journal • Tumor mutational burden

TMB (Tumor Mutational Burden) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CEBPA (CCAAT Enhancer Binding Protein Alpha)

IDH2 mutation • TMB-L

decitabine

16d

VEN-DEC: Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome (clinicaltrials.gov)

P2, N=235, Terminated, M.D. Anderson Cancer Center | Trial completion date: Dec 2027 --> Mar 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2027 --> Mar 2026; <75% participation

16 days ago

Trial completion date • Trial termination • Trial primary completion date

TP53 (Tumor protein P53)

TP53 mutation • TP53 deletion

Venclexta (venetoclax) • decitabine

20d

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker (clinicaltrials.gov)

P2, N=112, Not yet recruiting, The Methodist Hospital Research Institute | Initiation date: Jul 2025 --> Apr 2026

20 days ago

Trial initiation date • IO biomarker • Minimal residual disease

Venclexta (venetoclax) • cytarabine • azacitidine • decitabine

20d

DNA methyltransferase inhibition is a therapeutic vulnerability in VHL-deficient renal cell carcinoma cells. (PubMed, Exp Mol Med)

US Food and Drug Administration-approved DNMT inhibitors, such as decitabine and azacitidine, and investigational agents including RX-3117 and SGI-1027 selectively suppressed the growth of VHL-deficient RCC cells. Further mechanistic analysis showed that KCNK3 reactivation triggers TNF-α, MAPK and apoptotic signaling pathways, contributing to the observed synthetic lethality. Collectively, these findings establish DNMT inhibition as a synthetic lethal strategy in VHL-deficient RCC and highlight a potential therapeutic vulnerability for personalized treatment approaches.

20 days ago

Journal

TNFA (Tumor Necrosis Factor-Alpha) • VHL (von Hippel-Lindau tumor suppressor) • EPAS1 (Endothelial PAS domain protein 1) • DNMT1 (DNA methyltransferase 1)

azacitidine • decitabine • roducitabine (PCS3117)

21d

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory (clinicaltrials.gov)

P1, N=54, Recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> Jul 2027 | Trial primary completion date: Feb 2026 --> Jul 2027

21 days ago

Trial completion date • Trial primary completion date

Keytruda (pembrolizumab) • Venclexta (venetoclax) • decitabine